Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis

Fig. 1

Serum IFN activities of treatment-naive SLE patients and other treatment-naive rheumatic disease patients. Serum IFN activities were measured in treatment-naive SLE patients (n = 40), other treatment-naive rheumatic disease patients (n = 59), and healthy individuals (n = 33) by WISH bioassay and were presented as an IFN activity score. None of these patients and healthy individuals has a history of glucocorticoid administration. The multi-group comparison was done by the Kruskal-Wallis test with Bonferroni correction. p values < 0.05 were considered significant. HC, healthy controls; IFN, type I interferon; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis

Back to article page